BVNKF - SIGA Emergent Tonix rise amid Monkeypox outbreak

Drugmakers targeting vaccines and therapeutics for Monkeypox are trading higher in the morning hours Thursday as countries from the U.S. to Portugal report more cases of the virus. The U.S. has confirmed one infection and 13 suspected cases are under investigation in Canada. Portugal and Spain have confirmed five and seven cases, respectively. Notable gainers include, SIGA Technologies (SIGA), the maker of tecovirimat oral therapy for the infection and Tonix Pharmaceuticals (TNXP) a developer of a vaccine for both smallpox and monkeypox called TNX-801. Meanwhile, vaccine maker Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) announced on Wednesday that the U.S. has exercised the first options under its contract to procure a freeze-dried version of its Jynneos smallpox vaccine which is also indicated for Monkeypox. Emergent BioSolutions (NYSE:EBS) a rival of Bavarian Nordic (OTCPK:BVNKF) with its ACAM2000 smallpox vaccine is also on the rise. A relative of smallpox, Monkeypox is a rare viral infection

For further details see:

SIGA, Emergent, Tonix rise amid Monkeypox outbreak